rotation.to
Following this device: dark.
Free account
rotation.to
Sign in / Request free access
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

The company

Ensysce Biosciences, Inc.

ENSC · Nasdaq

Health CareBiotechnologyAbove a falling average

ENSC stood above a rising 150-day average in 0 of the last 52 weekly readings. It is 28.9% above that average now. Biotechnology: 16% of its 561 stocks in an uptrend (−15 points in four weeks); Health Care: 26% (−10 points in four weeks).

SEC filings

Statistics

Rotation
Above a falling average
Weeks in an uptrend
out for 52
Industry in uptrend
16% -15 in 4 wk
Insider buys, 12 months
$888K
Insider sales, 12 months
$0
Officials’ trades on record
0
Institutions holding
14 (+1)

In the rotation

Each square a week: lit when it closed above a rising 150-day average. 0 of 52 weeks.

20 Apr – 19 Oct
17%28%39%Apr 26Jun 26Jul 26Sep 26Oct 26

Biotechnology: Few of its stocks are in an uptrend and the share has fallen sharply over four weeks. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.

Money in and out

1 Nov 2024 – 1 Oct 2026
$0$473KNov 24May 25Nov 25Apr 26Oct 26

Open-market buys above the line and sales below, in dollars.

Congress and officials

No member of Congress or official has disclosed a trade in it.

Insiders

Buy orders, 12 months2
Sale orders, 12 months0
Buyers · sellers1 · 0
WhoDidSharesTraded
Bob G. GowerDirectorbought400,000at $0.4957 Aug 2026filed 18 Aug 2026
Bob G. GowerDirectorbought508,614at $0.48423 Apr 2026filed 18 Aug 2026

Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.

Institutions

Holders14+1 on the quarter
New · exited3 · 2
Reported value$218K

Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.

ManagerSharesChange
JANE STREET GROUP, LLCadded · filed 14 Aug 2026208,833$61K+195,263+1438.9%
ADAGE CAPITAL PARTNERS GP, L.L.C.unchanged · filed 14 Aug 2026149,711$43K00.0%
PERCEPTIVE ADVISORS LLCunchanged · filed 14 Aug 202686,666$25K00.0%
CITADEL ADVISORS LLCadded · filed 14 Aug 202686,193$25K+28,830+50.3%
XTX Topco Ltdadded · filed 14 Aug 202677,005$22K+52,642+216.1%
GEODE CAPITAL MANAGEMENT, LLCreduced · filed 12 Aug 202662,188$18K-11,692−15.8%
SUSQUEHANNA INTERNATIONAL GROUP, LLPnew · filed 14 Aug 202634,280$9,941+34,280
TRU INDEPENDENCE ASSET MANAGEMENT 2, LLCunchanged · filed 11 Aug 202613,000$3,77000.0%
TWO SIGMA SECURITIES, LLCnew · filed 14 Aug 202612,953$3,756+12,953
VANGUARD CAPITAL MANAGEMENT LLCunchanged · filed 13 Aug 202612,854$3,72800.0%
31 Dec 2024 – 30 Jun 2026
71115Dec 24Jun 25Sep 25Mar 26Jun 26

Everyone who traded it

Bob G. Gower Company insiderDirector · last 7 Aug 20266 · 0
Adam Levin Company insiderDirector · last 23 Jun 20220 · 0
Andrew Benton Company insiderDirector · last 23 Jun 20220 · 0
Curtis Rosebraugh Company insiderDirector · last 23 Jun 20220 · 0
Lee M. Rauch Company insiderDirector · last 23 Jun 20220 · 0
Steven Robert Martin Company insiderDirector · last 23 Jun 20220 · 0
William H. Chang Company insiderDirector, 10% owner · last 23 Jun 20220 · 0
Lynn Kirkpatrick Company insiderChief Executive Officer · last 26 May 20222 · 0
David Carl Humphrey Company insiderChief Financial Officer · last 17 Feb 20220 · 0
Kevin Geoffrey Birkett Company insiderChief Commercial Officer · last 17 Feb 20220 · 0
Linda Pestano Company insiderChief Development Officer · last 4 Feb 20220 · 0
A. Lorne Weil Company insider10% owner · last 30 Jun 20210 · 0

Same industry

MRNA ModernaLeading+154%
IOVA Iovance BiotherapeuticsLeading+133%
ABCL AbCellera BiologicsLeading+61%
ENTX Entera BioLeading+49%
HALO Halozyme TherapeuticsLeading+46%
XERS Xeris Biopharma HoldingsLeading+46%
HELP Helus PharmaLeading+37%
XNCR XencorLeading+32%

Distance from each stock’s own 150-day average.

Government contracts

No federal award is tied to it.

From its SEC filings

Operating profit marginFY 2025 · to 31 Dec 2025-202%
Free cash flow marginFY 2025 · to 31 Dec 2025-157%
Research spendFY 2025 · to 31 Dec 2025205%
Share count trendFY 2025 · to 27 Mar 2026103%
Cash and equivalentsFY 2025 · to 31 Dec 2025$4.3M
Free cash flowFY 2025 · to 31 Dec 2025−$7.9M

Analyst forecasts

No analyst forecasts yet.